397 related articles for article (PubMed ID: 11685722)
1. Preclinical mechanisms of action of docetaxel and docetaxel combinations in prostate cancer.
Pienta KJ
Semin Oncol; 2001 Aug; 28(4 Suppl 15):3-7. PubMed ID: 11685722
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel and docetaxel in prostate cancer.
Obasaju C; Hudes GR
Hematol Oncol Clin North Am; 2001 Jun; 15(3):525-45. PubMed ID: 11525295
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of action of taxanes in prostate cancer.
Stein CA
Semin Oncol; 1999 Oct; 26(5 Suppl 17):3-7. PubMed ID: 10604261
[TBL] [Abstract][Full Text] [Related]
4. Targeting bcl-2 gene to delay androgen-independent progression and enhance chemosensitivity in prostate cancer using antisense bcl-2 oligodeoxynucleotides.
Gleave ME; Miayake H; Goldie J; Nelson C; Tolcher A
Urology; 1999 Dec; 54(6A Suppl):36-46. PubMed ID: 10606283
[TBL] [Abstract][Full Text] [Related]
5. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.
Sinibaldi VJ; Carducci MA; Moore-Cooper S; Laufer M; Zahurak M; Eisenberger MA
Cancer; 2002 Mar; 94(5):1457-65. PubMed ID: 11920502
[TBL] [Abstract][Full Text] [Related]
6. Survival of docetaxel-resistant prostate cancer cells in vitro depends on phenotype alterations and continuity of drug exposure.
Makarovskiy AN; Siryaporn E; Hixson DC; Akerley W
Cell Mol Life Sci; 2002 Jul; 59(7):1198-211. PubMed ID: 12222966
[TBL] [Abstract][Full Text] [Related]
7. ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells.
Zelivianski S; Spellman M; Kellerman M; Kakitelashvilli V; Zhou XW; Lugo E; Lee MS; Taylor R; Davis TL; Hauke R; Lin MF
Int J Cancer; 2003 Nov; 107(3):478-85. PubMed ID: 14506750
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel in prostate cancer.
Small EJ
Anticancer Drugs; 2001 Feb; 12 Suppl 1():S17-20. PubMed ID: 11340899
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel in the integrated management of prostate cancer. Current applications and future promise.
Logothetis CJ
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):63-72. PubMed ID: 12108899
[TBL] [Abstract][Full Text] [Related]
10. Differential effect of anti-apoptotic genes Bcl-xL and c-FLIP on sensitivity of MCF-7 breast cancer cells to paclitaxel and docetaxel.
Wang Z; Goulet R; Stanton KJ; Sadaria M; Nakshatri H
Anticancer Res; 2005; 25(3c):2367-79. PubMed ID: 16080463
[TBL] [Abstract][Full Text] [Related]
11. Docetaxel (taxotere) in the treatment of prostate cancer.
Beer TM; El-Geneidi M; Eilers KM
Expert Rev Anticancer Ther; 2003 Jun; 3(3):261-8. PubMed ID: 12820771
[TBL] [Abstract][Full Text] [Related]
12. Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts.
Oudard S; Legrier ME; Boyé K; Bras-Gonçalves R; De Pinieux G; De Cremoux P; Poupon MF
J Urol; 2003 May; 169(5):1729-34. PubMed ID: 12686819
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of androgen-independent hormone refractory prostate cancer using docetaxel].
Miyoshi Y; Uemura H; Kubota Y
Nihon Rinsho; 2005 Feb; 63(2):298-302. PubMed ID: 15714982
[TBL] [Abstract][Full Text] [Related]
14. Cellular bases of the antitumor activity of the novel taxane IDN 5109 (BAY59-8862) on hormone-refractory prostate cancer.
Cassinelli G; Lanzi C; Supino R; Pratesi G; Zuco V; Laccabue D; Cuccuru G; Bombardelli E; Zunino F
Clin Cancer Res; 2002 Aug; 8(8):2647-54. PubMed ID: 12171897
[TBL] [Abstract][Full Text] [Related]
15. Variation in the kinetics of caspase-3 activation, Bcl-2 phosphorylation and apoptotic morphology in unselected human ovarian cancer cell lines as a response to docetaxel.
Kolfschoten GM; Hulscher TM; Duyndam MC; Pinedo HM; Boven E
Biochem Pharmacol; 2002 Feb; 63(4):733-43. PubMed ID: 11992642
[TBL] [Abstract][Full Text] [Related]
16. Recent progress in the clinical development of docetaxel (Taxotere).
Hortobagyi GN
Semin Oncol; 1999 Jun; 26(3 Suppl 9):32-6. PubMed ID: 10426457
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
Petrylak DP
Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2.
Friedland D; Cohen J; Miller R; Voloshin M; Gluckman R; Lembersky B; Zidar B; Keating M; Reilly N; Dimitt B
Semin Oncol; 1999 Oct; 26(5 Suppl 17):19-23. PubMed ID: 10604264
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel, estramustine, plus trastuzumab in patients with metastatic androgen-independent prostate cancer.
Small EJ; Bok R; Reese DM; Sudilovsky D; Frohlich M
Semin Oncol; 2001 Aug; 28(4 Suppl 15):71-6. PubMed ID: 11685733
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer.
Hussain M; Smith DC; El-Rayes BF; Du W; Vaishampayan U; Fontana J; Sakr W; Wood D
Urology; 2003 Apr; 61(4):774-80. PubMed ID: 12670564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]